Eporen 5000 IU Injection

Overview

Eporen 5000 IU Injection contains Erythropoietin Alfa (Epoetin Alfa), a recombinant human erythropoietin manufactured by Square Pharmaceuticals PLC. Erythropoietin is an endogenous glycoprotein hormone produced by the kidneys that stimulates red blood cell (RBC) production from bone marrow progenitor cells. Epoetin alfa is biosynthetically identical to naturally occurring human erythropoietin and is used for the treatment of anaemia associated with chronic kidney disease (CKD — both dialysis and non-dialysis patients), anaemia due to cancer chemotherapy, and anaemia in patients scheduled for major elective surgery to reduce the need for allogeneic blood transfusion.

Dosage and Administration

Adults — CKD anaemia: initial dose typically 50–100 IU/kg three times weekly (subcutaneous or IV); maintenance doses adjusted to maintain haemoglobin 10–12 g/dL. Cancer chemotherapy anaemia: typically 150 IU/kg three times weekly SC. Doses are always individualised under specialist (nephrologist or haematologist) guidance.

Interaction

NSAIDs and ACE inhibitors may reduce erythropoietin efficacy. Iron supplementation is often required concurrently — adequate iron stores are essential for erythropoietin response. Cyclosporin levels may increase as haematocrit rises.

Contraindications

Contraindicated in uncontrolled hypertension, pure red cell aplasia (PRCA) following prior erythropoietin use, known hypersensitivity to epoetin alfa or any excipient, and in use for haemoglobin targets above 12 g/dL.

Side Effects

Hypertension (most common), headache, flu-like symptoms, and injection site reactions. Thrombotic events (stroke, myocardial infarction, deep vein thrombosis) — risk increases when haemoglobin exceeds 12 g/dL. Pure red cell aplasia (PRCA) — rare but serious.

Pregnancy and Lactation

Limited safety data in pregnancy — use only if clearly indicated and benefits outweigh risks under specialist supervision. Not recommended during breastfeeding.

Precautions and Warnings

Monitor haemoglobin regularly — do not target above 12 g/dL (risk of cardiovascular events increases). Check and correct iron, folate, and B12 deficiency before and during treatment. Monitor blood pressure throughout therapy.

Storage Conditions

Store at 2–8°C (refrigerate). Do not freeze. Protect from light. Do not shake.

Frequently Asked Questions

Why is iron supplementation usually given with erythropoietin therapy?
Erythropoietin stimulates rapid RBC production, which rapidly depletes iron stores; without adequate iron, the bone marrow cannot respond optimally to the erythropoietin stimulus, and iron supplementation is required for the full treatment response.

What is pure red cell aplasia (PRCA) and how is it related to erythropoietin?
PRCA is a rare but serious complication where the immune system generates antibodies against erythropoietin, destroying both the administered drug and the body's own erythropoietin, resulting in severe anaemia; it requires immediate discontinuation of erythropoietin and specialist management.

This content is for informational purposes only and does not substitute professional medical advice. Please consult a registered physician before taking any medication.